When Does Orladeyo Patent Exclusivity End?
The patent for Orladeyo (berotralstat) is set to expire in 2035 [1]. This indicates a significant period of market exclusivity for BioCryst Pharmaceuticals.
What is Orladeyo Used For?
Orladeyo is a once-daily, oral therapy approved for the preventive treatment of hereditary angioedema (HAE) in adult and adolescent patients 12 years and older [2]. HAE is a rare genetic disorder that causes unpredictable and often severe swelling attacks [3].
What is the Significance of Patent Litigation for Orladeyo?
Patent litigation can impact the timeline for when generic versions of a drug can enter the market. Challenges to a drug's patent can lead to earlier generic competition, affecting the revenue and market share of the originator company. However, as of now, specific patent litigation details for Orladeyo in 2025 are not readily available in the provided information, beyond the stated expiry date of 2035 [1].
How Does Orladeyo Work?
Orladeyo is a plasma kallikrein inhibitor. By inhibiting plasma kallikrein, it is believed to prevent the overproduction of bradykinin, a mediator that contributes to the swelling characteristic of HAE attacks [2].
Who Manufactures Orladeyo?
Orladeyo is developed and manufactured by BioCryst Pharmaceuticals [2].
What are the Alternatives to Orladeyo for HAE?
While Orladeyo offers an oral preventive treatment option, other HAE treatments are available. These include intravenous and subcutaneous self-administered therapies. Some are used for acute attack management, while others are for prophylaxis [4].
What is the Timeline for Orladeyo's Market Exclusivity?
Orladeyo was approved by the U.S. Food and Drug Administration (FDA) in December 2020 [2]. Its primary patent is listed to expire in 2035 [1].
---
Sources:
1. DrugPatentWatch.com
2. BioCryst Pharmaceuticals, Inc.
3. National Organization for Rare Disorders (NORD)
4. Hereditary Angioedema Association